Author of

• 17556

  +

  P2.03a - Poster Session with Presenters Present (ID 464)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17622

    +

    P2.03a-066 - Pemetrexed(P) in Third and Fourth Line Chemotherapy for Advanced Non-Small Cell Lung Cancer (Non-Squamous)-aNSCLCns (ID 4638)

    14:30 - 14:30  |  Author(s): A.C. Grigorescu
    • Abstract

    Background:
    Platinum-based chemotherapy remains the standard first-line treatment for a NSCLC. A standard for second-line chemotherapy could be docetaxel or pemetrexed. Third and fourth line of chemotherapy is poor defined.
    
    Methods:
    42 patients (Pt.) were included in the study. Pt. were enrolled successively by the date of coming into the clinic All Pt. had assessment of response after 2-3 cycles of chemotherapy. First line consisted of: P plus carboplatin. P in mono-therapy was used in second, third and fourth line. 26 Pt. (Group A) were evaluated after first and second line of treatment. 16 Pt. (group B) were evaluated after third and fourth line. Overall survival was calculated for patients included in each line of therapy using Kaplan Meier curve.
    
    Results:
    Group A: 13 men and 13 women, median age 57 years (37-81), 3 patients in stage IIIB and 23 stage IV, ECOG performance status=I for 20 Pt. and 2for Pt.=2, for 6Pt.Hystopathology: 25 adenocarcinomas and 1 large cell carcinoma; 12 smokers and 14 nonsmokers. First line consisted of: Paclitaxel + Carboplatin 11 (42%) Docetaxel + Carboplatin four (15%), Carboplatin + Vinorelbine 3 (12%), Pemetrexed + Cisplatin 2 (8%), Gem + Cys 2 (8%) other 4 (15%). The median number of cycles in first line was 4 (2-4), in second line 7 (2-24). Overall survival in first line: 12 month; in second line: 10 month. In group B group: 12 men and 4 women, median age 62 years (31-80) .4 patients had stage IIIB and 12 stages IV, the histopathology was adenocarcinoma for all. ECOG performance status for all Pt. in first line of chemotherapy was I. First line chemotherapy was similar to group A except 3 Pt. treated in second line with Erlotinib and 2 cases treated with bevacizumab+paclitaxel and carboplatin. Median overall survival in this group was 6.5 months. Toxicity was no more than 2 on the WHO toxicity scale.
    
    Conclusion:
    In selected Pt. with aNSCLCns namely those who responded to the first and second line chemotherapy or erlotinib, P can be administered in third and fourth line with survival benefits and acceptable toxicity. A large studio is necessary to confirm the data obtained in this study. Once again highlighting the need of a marker of response to chemotherapy.